REGISTERED COMPANY NUMBER: I)4569174 IETrl•nd WalÈsl REGISTEREOCMARITY NUMBER: 1100154 ItEPORT OFTNeTRUSTEESAND F114ANCIAL STATEMENT5 FQI¢THE YEAReNOED 31 OCTobER 1015 FOR ¢URE LEUKAEMIA J W Hlnks LLP Chartoted Accountant5 nd Statutory Avditors 19 Highfield Road Ed8baston 8irmin8ham West Midlands B15 3BH CURE iEUKAEMIA COMTENTS OF THE FIP4A14CIAL5TATEMENTS FOR ThE YEAR ENDED 31 ocfoBER2025 P• Ch•lNMTr's Report Report oftheTrus¢M5 3 tg 8 Reportof the Indep•r*l•nt Aydlt 9 to 11 Stat•m•ffltof Fln•nchl AciMtl•s 12 Bal•TrK• Sh•rf 13 Cash FI￿t$￿te￿*￿t 14 Not•Jtp the f•sh HowStstwTr•nt 15 14ot•i toth• FINnc￿l St*t•ffj•nti 16 to 26 CURE LEUWMIA CHAIRMAN'S REPORT FOR THE YEAR ENDED JI OCTOBER 2025 13m pleased to report another year of steady progress, where we have once ègèin delivered on our core ftnanclal commttmqnts to hJThd Cure Leukaemla Research NuT5es via Acceleratln8ainical Tflals (A￿> to enable cllnlcal trialsto open. We are becoming more diverse in our intome generatlon. de-Tiskln8 our core events and Imwovin8 our overall 8overnance of thÈ tharlty wh115t impro￿ngthe overall long-term Infrastructwe of the chaf Real 5ucce55 and lon8-term financial 5USt3inabilhy wlll be achieved when we are recognised a5 3 major national charltyi viherèby donofs are donètlng either one off or re8ularly at volurne a5 well as fundln8 fiom more Trust5 and Foundatlons, and reduting the ellance of Income from ￿eThts or8Jnised by ourselves. with 250,CQO people In the UK Ilvln8 Wlth blood cèncer, our chillenge and foru5 IS tD be wpported by ès many of those as possible to ultlmitEly brlng us closer to a Cure by provldln8even more fundlngto enable more cllnical trials to 0￿￿. Our partnership wlth Accderètlng aiThical Trta15 (A￿) contlnues to dewelop and we ère dell8hted thot cur fundln8 has enabled the openlng In June 2025 of 2'EVOIVE tr1315 whlch refert? a new serles of cllnlcal trials fL>r Acute Myeloid Leukaernla IAMLI whlch aim to provlde more perwnall2ed and le55toxic treotment optlons, partlculèrlylor pètlents unable t¢ yndpr80 tradltlonal chemotherapv. These trla15, developed wlth the HOVON group, wlll fo£us on patlents wlth IlmitÈd treatment cbolces and represent 3 518nMcant dvancement in Improvln8 care and outcome5 forAML patlents, Such Internotional trlals are onty able to be opened vl¥ our contlnued 5UPPOrt ol the TAP and IMPA￿ n*tworks at leadSn8 blood cancer centres •crossthe UK. In addltlon to new trlals beln8 announced this year, findln8s frorn 4 of the ex15tin8 trials that our fundin8 hos enabled to run wert presented at the world-renowned American So¢leiy fcr HaeMatol0￿ conference to 40,OCQ delegates In December. One of those tTla15 presented wa5 theAMMOtrlal led by Or Oan WI5ernan from The Christle H05pltal thattW5t5a new drug In treatln and extendln8 the Ilve5 of patients wSth a rare bone rnarrow Cèncer, where tre*ment optlens are very Ilmited. In Aprll 2025 the trl•l was officlalty c105ed, ￿th a total of 75 patlents téln8 rKrulted. We havo also been able to cmflrm the appolntrnent of thefirst role for OUT transplant trials ATICUS network. Th1$ key role wlll wo In partnershipvitth our 11 ¢hlldren'5 hospltals to lead on ihe dellvery and openlng of now trlals for thlldrw wth bl¢od cancer. We have seen overall 8ross Income Increase from £2.918.464 to £3.709.IS8 wlth tle Increase beln8 drlven by cor• Lyclln8 events, 1¢8acy Income and an in¢rea5e in donatlons frem Indlvlduals, Increasing from £76.146 to £467,105. ExpÈndlture has Increased from £2,906,092 to É3,617,294. malnly due to an uplllt In our nurslng grant commltment5 of £529,482 from the prlor year o+ £302,796 t¢ £832.278, In the year we have a150 seen Inrrea5e In employee costs as well as ¢oststO UP8rade our webslte. Our rycling events remaln a key driver of our fundrèlsln8 income and we hève seen pleasln8 growih In our female tour de Fr•nc* eventThe Route w￿h 12 rlders taklng part In 2025 compared te 4 rlders In It5 first year In 2Q24. For theyear ahead, we have 21 riders tskim8 partwhlch wlll seeourfundraisin8 Potentlal from this event contlnue to Increase. We are a150 dell&hted to have announced our first ever global partnership with Flutter EntertaiThmentwhlch sees them extend thelr supwrt lor TheTovr21 a5 well as our running events for a further 3 year5. Our runnlnB events programme contlnues to make very poSit￿e proEre55 Wlth 200 runners taklng part in the Pads maTathon wlth iunner5 from 29 countries representlng us and we are confldent of 5eelng further growth of thls event and other intemational 3rd party runningevents in theyear ahead. We are a150 extremely 8rateful for the continued generous support frDffl The Syncona Foundation. Gèrfield Weston Foundalon, The Broome Family Charitsble Trust and The Acce55 Foundatlon wlth gronts totsllln8 £315.LKIO. Aswe look to move our current over reliance on event fundin& we See grants from Trusts and Found*ions as another area offocus forthe year a￿ad. Page L CiIRE LEUKAEMIA CHAIRMANS REPORT FOR THE YEAR ENDED 31 ocf08ER 2025 In the last 12 month5 we have Invested In oui Infi&stru¢ture with the appllintment of a new full tlme Graphlc De518ner, 8usSness evelopmÈnt Manager and bfully up8raded web&t&. Our new gr3phlc desianer now prO￿deS us with an all-year-round Inthou5e5klll set t￿t enswes we can be moTt efflclent and more cost effective Dn our creatfve and design reouliements, Our new BU￿￿eSS Dwelopment Mana8erlsfottssed on 5qcurln8 predomlrwntly bn8-term ¢orporatefiJndln8forour ATICUS network vla our Club 10 SnStlalve. whereby companles look to ￿edge £IO,QOD per year Ilnked to tholr re5pectlve lotal chlldren's hospltsl. Our prevlous Webs￿ was notffit for purpose forour lot)g-ierm plan5 and wlth the upgrad4 thot has been undertsken, we now have web51te that Is more reflertlve of a naugnal and professlonal entity. knawl Thank5 a5 ever to our Board olTrustees, and out CLt•am led by our CEOJame5 McLau8hlln who all werk ilrelessly on behalf of ow cllnld¥ns, nur5e53nd patients. Page 2 CURE LEUKAEMIAIPEGisfEREO NLIMBER: 045691741 REPORT OFTHE TRUSTEES FOR THE YEAR ENDED 31 OCTOBER 2015 The trustees whe are a150 dlfectors of the charityfor the purposes of the Companies Act 20061 present thelr report with the flnanclal statementsofthe charityfDrthe yearended 31 Ortober 2025. Thetrurtees have adopted the prov151ons ofAccounbngand ReporUn8 by ChèrllSes." Statement of Recommended Pf3ctice appllcable to Charl￿e& preparln8thwr accounts in accordance with the Flnèncial Reporting Standard applicable in the UK and Republpc of IrÈland IFRS 1021 leffectfve I january 2Q191. OBJECTIVES AND AcnvmES Oblectlves and alms Cure lÈuk3emla's objects and printlpal activitle5 ore to help provlde relief to persons sufferln8 from leukaemi3 and tr* undertake research into the causesi prevention and treatmentof leukaÈmla and to pub115h the usefvl resuks of such research. rs our alms We rewew our aims. oblectives 3nd aCt￿ltIeS each year. Thls revlew leoks at what we aChI￿ed and 0￿coMeS of our work In the previous 12 months. The revlew looks at the 5ucce55 of each key actlvity and thè beneflts they have brought to those 8raup5 of people we are set upto help. The r￿e￿ also help5 UStoen5yre that ouralm, oblettwes and a£tlYitles femained focused on our ststed purposes. We have referredtothe guldancecont•lned In the CharltyCommlsslon'$8eneral 8uidènteon publlc be[￿1When reYlewln8 our alms and objectives and in plannlngour future•¢Uvltles. In partlcular, the trusteesconshler how planned actl¥ltlEswIII contrlbuteto the alm5 and objèctlves they hav8 set. The focu50f the charity contSnuesto be the provlslon of help to provide rellef to per50n5 sufferin8fmm leukaemla andto undertake research Into the causes, prevention and treatment of ieukaemla and to pub115h the u58fv1 resuks of such research. In ordei to achieve its objects. the charty has contlnued to adopt the followln8 Strate81¢ obl*2tlves. To fund the yovlslon of new therapies and treatmentslor lÈuk•emla pat￿ntS across the Unlted Kingdom. To enablÈ sclentSsts and cllnl¢lans te work even c505er tO8etheito dewelop ne¥v tre•tments for IeukaeM￿. To provlde an Informatlon and resource centre for leukaemia. To provlde supportgroupsfor leukaemia patlent5 and their famllles. To e$tabllsh an endowment to fund thls work over the next 10 yEars. Gr*him•klTh8 The tharlty revlew5 variousorganlsatlons and Indlviduals who support and delfver the charlty'$ obhtts, PotentSal recipient5 of grants pald by the charlty are revlewed b¥ ¢harlty on a £asfrby-ca$e basis dependinB upon the a¥allable resources of the charlty. ACHIEVEMENTS AND PERFORMANCE Dpvelopments, artMtle5 Ind ath1t￿ments durkni the ye•r Our maln activitle5 and v4ho we try to help are described below. of our charitable attlwtle5 focus on our ablllty to hÈlp F¥ovide relief to per50nssufferin8from leukèemlaandto undertake research Into thec•useS+ prevention andtreaimentofleukaernia thiou8h the use of the fKllltles avallable to the charlty. Page 3 CLIRE LEVKAEMIA IREGISTERED NUMBER.. 045691741 REPORTOFTHETRUSTEES FOR THE YEAR ENDED JI OCTOBER 1015 Summary of key cllnlcal highllghts ènd the tmpattof Cure Leukaemlafundlng.. TAP (Trials Acceleration Programmel has transformed the recrultmentto Complex cllnlcal trlals wlth over 1,600 patients recrulted since establishment of TAP in 2012. Facllltited patSent access to more than £250 million free drugs at no cost to NHS. Trial sÈt up times have 5ubstsntialty reducÈd. ￿er￿n8thatTAP Is deliver1￿0cce1erèt7On Compared to the publlshed average of Z.5 veaT5. TAP has seryed ès a ma8netfor Inward Investment by the global pharmaceutlcal sector and Increased Interest from gbbal pharmaceutlcal partners In wov151on of registratlon enablin8trial data. 4 new trials openÈd In the last 12 monthsfor AML CLLand Myeloma called Evolve 1& 2, PRECISE ènd TOPICAL whlch are all Internatlonal collaboratlons Includln8 Australla, Germany. US. Netherlands and Belglum suppwted by global pharma such as Pfizer, HOVON, Astrazeneca and 5anofi. Orb5tlcall¥ Incr¢05ed the number of clinlcal tr131s that can ￿ fa¢i1lt•ted. and the Volume of trlals that can be eondutted ccncurrenfjv. Drastlcally reduce the travel distances required by people to reach thelr nèarest hOsp￿al across the UK. Drastically intrease the speed at whith cllnlcal trla15 can move through to UK and global 5tandèrd care. Ensure the èbllltyfor 5tabllhy and plannin8 In the medlum temi forfunde(I Cure LeukaEmia Rese•r¢h Nurses to conduct Cllnicèl trlals arr055 the UK. E¥enti Strit It15 Important that we toThtinue to 8row our core events by Increased partlcipation but also It)crea5e the breadth and depth of the type and nurnber of wents that we put on, Durin8 202S we made signlfkant pro8re5s In expandlw our core events. FINAN￿￿ REVIEW Nn•nclal posltlon The'StatemÈnt of Flnènclal Activitle$ shows voss income of £3.709,15812024.. £2,918,464) and expendlture of £3,617,29412024.. £2,906,092) before reallsed and unreali5ed 8ain5 and losses on fixed asset Invesiment5 for the y*ar ended 31 0¢￿bE￿ 2025. The net surplu5 fortheyear èmounted te £105,27812024.' net Surplus 01 £28,899) ofter the Inclu51on ef reolised and unreallsed 6alns 4nd105ses on li¥ed asset Investments. Totsl fund5 carrleé forward amount to £563,06812024.' £457,790). The reserv45 are ylmarily to cover the devdDpment and future runnlng expenses of all aspects of tho charlty, and the present level of fundin815 consldered to be adequote to support the contlnuètSon of our exlsting aCtl¥lt￿s. Investment pollcy •nd ab1￿11¥e1 The chaflty has adopted an Investrnent poll¢y to try and achlewe the followlng twoflnanclèl obhctlves. To generatea su5talnable return on Investments usln8 a cèutious InvestmEnt approach. 11 possSble, withln the thaflty's overoll cautious approach to investmpnts, to ensurÈ that the charity's lThvestments are sufficient to meet any obll8atlorys the charity has to fund research nurses, expenditure. The charity has also adopted an ethScal approKh to Investments. As a result, no Invesimenrs are to be made by the charty In busine$5es Involved in tradln8 in alcohol, tobacco, pornography, armarnents or gamblln8cr in bu51npsse5that are involved onlmal wplfare abuse. hurnan rl8hts abuse or attrvlties that do rK*t take into account the sanctity ol l+fe. R•serves pdlrv The charity would like to maintain unrestrltted funds not cornmitted or Invested In tangible flxed ass¢ts, whlch are the free reserve5 of the charlty, at a thl which equate5 to between & and 12-months unrestrfcted Èxpenditure. Thls providgs sufficient funds to over mana8ement and adrnini5tratlon and support costs. Thi5 alm has to be evaluated a8alnst the objects of the charity and their fultjlment. KEY HIGNIIGHTS FOR THE YEAR AHEAD We hawe launthed a new podcast Series tltled Let's Talk Blood Cancer- The Patlents, Podcast. The aim of the podcast Is to educate nd infortn bltiod cancer patients and to be èiru5ted source of information forthem. Itwill also wovide us with the plarfufm to 5harÈ informatlon aboutthe pro8res5 bein8 rnade In clinical trSals ¥vhi15t ralsin8awareness ofcure Leukaernia natlonalty and Internationallv. We look to see Increased growth ￿n our core runnin8 events and will be looklngto capitalise onthp 2027Tuur de France andTour de France Femrne5 ￿eC Zwlft stsrtln8 in the UK by securing more riders for bDth events and by securing reglstrations earlier than in previous years. P3Ee 4 CURE LeuKAEMIA IftEGISTERED NUMBER.. 045691741 REPORTOF THE TRU¥tEES FOR THE YEAR ENDED Ji ocfoBER 2025 We are also immensely prcud to hwe been chosen as one 0151r Chr15 Hoy's charity partners for his Tourde 4 fundraising eventthat wlll take place In September alon85ide Pr0514te Cancer UK, Macmillan, Bread Cancer Now and Mag8les. The proceed5 from the eventwill look to 5UPPOrt Durfunding of ourATICUS network. From a cllnical per5pertive. we wlll be lookAn8 to announce the openinB of more cllnlcal trlals xross ourTAP and IMPAcf retworks and further establlshlng Cure Leukaemla as a nat￿nallY teco8nlsed charlty. 5fRUCTURE, GOVERIIANCE ANO MANAGEMENT G4)v¢rnlm8 document Cure Leukaernla 15 a compèny Ilmlted by guarantee (registered In Eniland Jnd Woles number IILN)1541 Incorpjrated on 22 October 2002 and was wven registered charitable statu5 on 20 Qctober 2004 Under thp Charitles kt 1993 Icharlty re8lstratlon number 45691741. The governln8 documents of the company are Its memorandum and artlcles of •ssotlation. Recrultment •nd appoifflment ol n•w tr￿lIeS Appolntments are made to thp board of trustee5 prlmarity vilth a view to enhon¢ln8 the management expethse gf the charlty. new trustee wlll be supplied wlth (Dpies of the charity's memorandum and artlcles of assoclatlon, piSor mlnutes and èccounts, an 0l8an1sat￿n chart and staff handbaok. The appolntment of trustees Is undertaken by appllcotlon and approval by the manègement comrnlttpe. The electSon of th maTha8emÈnt commlttee and elettion5 to officeis ofthe choilty take place at each Annual Ge￿ra1 Meetlng. All twst•e$ glve thelr ￿rne ¥oluntarlly and recelve no beneflts from the charlty. Any expenses reclalmed from the charlty are Set out in the notes to the flnanclal 5tstements. OrB4nls•t4on•l StI￿￿re and declslon m*kkni The dlre¢tors of ihe charltable company arè Its trustees for the purposes of charlty law. Thecharitsble ¢ompany Isgovernel by b board of trustee5. Tho responslbllityforthe day-to-dèyoperatlonof the¢haritablecompany Ile5 wlth the Staff team who are employed by the charltable company and aro resp0Th51ble to the trustee5. The management commlttee of trustees meet r¢8ularlyi retsln full and *ffecl¥e control over the ¢h•rltable company and monltor the executive rnana8ers. Being non-exÈcutlve diroctor5, they bring èn independent lud8•rnent to ￿ar on 155ue$ of sirategy, perform3nce and resour£es. Includln8 key appolntments and standards of conduct. JCWL•Fi Cure Leukaemia has a philosophy of maintainlng a lean and efFective organisatSon supported by effiripnteutslde partner5tD PrO￿de the maximum retum on the fundra15ingand sponsorshlp5 from people and companles who believe In us. Of course as the charity grow5, we need to make considered Investment in the organisation. During 2023 there were a number of changes with new startersjolnln8 the CL team, includin88 full tlme Head of Flnance and Operation5, who will be key In managingth cost5, Investment, and flnanclal effect uf our fundralslng initiatiVP5 for future growth. For the year ahead, whÈn and where appropriate, we will be looklng to further add to the organi5atlon at ts)th at an eKecutl¥e and board level to ensure we Eontinue to maximi5e the opportunlties are becoming availa￿et0 us as a national charilywith ambitlOUS growth plans. Page 5 CURE LEUKAEMIAIREGISTEREO NUMBER- 045691741 REPORT OFTHE TRUSTEES FOR THEYEAR ENDED JI OCfQBER 2015 STRu￿￿RE, fjOVtRNANce AND MANAGEtthlENT Inthrtloh *fid tAlnln8olnewtrusto2s Trurtees ère irwolved in ongoln8 general ond 5pecffic tralnlng accordln8to theSr areas of rgSPOnslbility. Key man•iement r•rnunoratlon In the tru5tees' opinlon, the key management personnel of the charity respon￿ble for dirÈctin& controlllr*& runnlng and operaung the charlty on o day-to-day basls con￿Sts of the Board ol Trustet5 and theCThief EXeC￿l￿e. nnel-T All trustees 8lve ol their tlme IreEly and no trustee recelved remuneratlon durln8theyear. DElJ115 of tru5tee5' expenses and rdated party transaction5 are dlsd05ed In the note5tc the ftnanclal st*ern?nt nn The pay of the charSty'S senlor staff Is revlewed annually and normalfy Increased based upon the positlon ol the charity's finances andthec05t of lI￿ngIngeneral. In view of thenèture ofthe charlty, thetrustee5 benchmark pay levelslnother51mllar or8anlsatlons Rlsk man•iqffleni The trustees have a duty to IdÈntfy and revlew the rlsks io whl¢h the charlty Is exposed and to ensure appropriate controls are In pkKe to provlde reasonable a55urance a8alnst fraud and error. Thetru5tqe5 hwe a rSsk mafia8ement strate8Y that compri%e$ the followln6. annval revlew of the risk5 that thecharlty may faci. The estsbllshment of systern5 ond procedures to rn￿16ate those rlsk$ Itlentlfied. The implementatlon ol pfotédures deslined to minim15t any potentlal Impa¢t on the charlty should those r15ks rnèterlallse, The trustees are ol the oplnkin th•tthere are no major rlskstv whlch the charlty is OXPOsed, Fundra151nB St•nd•rds Inform•tlon The majority of our Income tomes from Volunt￿ don*tlon$ from our supporters. Throu8h the fundr¥i5in8 efforts of eur staff. volunteers and supporters we are ieneratln8 the fin¥ncl•l resources to en•ble u5to pro￿de our servlce5. We have a wlde portfollo of fundralsing actlvlties to denerate voluntary donatlons towards the servltes we provlde. Our Board of TrustÈes Is deeply commlttEd to bulldln8 relatlonshlps and trust wlth our supporler5 and Is committed to the 5trengthenln8 Qf oversl8ht and assurance wn¢ernln8 our fundrèlsln8 prograrnme5 and In Ènsuring cornpilance and best practlce in these areas. We are partkularly aware of the need to protect vulnerable IndMduals In any fundralsin8we undÈrtake. We contlnue to be tornmltted to addressln8 any expressioTh ol dlssatislartion on the part of our stspporter5 and to examlnln8 Wav5 to Improve the Iqvels of our servlce to them. REFEREP4CE AND ADMIN15TIiATIVE DETAILS Re6lstered Company number 04569174 IEn*and and Wales) Rtyi#eted ChIr￿V Thjmber 1100154 Reilsttrtd office 19 Hi8hfipld Road Edgbastrjn rmln8hatn West Midlands 815 3BH Pa8e 6 CVRE iEUKAEMIAIREGlmRED NUMBER: Lb15691741 REPORTOF THE TRUSTEES FOR THE YEAR ENDED Ji ocfo8ER 2025 Tru51a•s G W Couslns Profe550r C F Craddock CBE DrGEOPratt R J Tvrnbull L M Shoaf P M Whiteheod M D t>oolin A Owens J C Murphv SMHope Dr P Mehts Chalrman Resl8ned 26 February 2025 Treasurer Pfofes50r C F Craddoth C8E. RJ Turnbull Ind L M Shoaf wlll be sublectto rtrelert5tsn at the Annual Generol Meetlng. Company Seu•tsry KAHJones J W Hlnks LLP Chartered Accountants and Statutory Audltors 19 Mighfleld Road Edgbastvn "rmlnBham West Midlands B15 3BH Solldt Talbots Law Llmlted 25127 Flagley Road Stourbrldle DY8 IQH b•nk• HSBC 130 New street 8irmlngharn West Mldlands 241U In¥*stm•nt M•nwr FORM Flnancial Clarlty Limited Nii.1 The Paddock5 Impney Estate Drolts¥ich WDreestershlre WR9 OBL Chl•f Executlve J W McLau8hlln UA￿1￿ OFTHE MÉMBERS 140 trustee has any beneficial Interest In thechatltable company. The liabiiiiyef the members is Ilmited to their8uarantee. Inthe event of the company being wound up durlng the period of their mernbership* members undertake to contrlbutÈ such amount as ffiay be requlred not exceeding £10. Pa8È 7 CURE LEUKAEMIAIREGISTERED NUMBER-045691?41 REPORT OFniE TrUSTEE5 FOR ThE YEAR ENDED 31 ocfoBER 2025 5TATEMENf OF TR￿eE5. RESPONSIBILITIES The trustees (who are also the directers of Cur@ LeukèÈmia for the purposes of cornpany lawl are re5ponslble for preparlng the Annual Report and the flnanclal statements in accordance with applicable law and Unlted Kln8dom Accountlng Standards Iunited Klngdom Generally Accepted Accountin8 Practlcel Includlng FlThanclal f¢eporting Standard 102 'ThE Finandal Reportin8 Standard ppllcable Sn the UK and Republic of Ireland Company law requires the irustees to prppare flnanclal ststements for pachfinandal year. Underthèt law, thÈ trustees have dected to prepare the financial st*ements In accordance wlth Llnited Klngdom Generally Accepted ActouThtin8 Practlce Iunlted Kingdorn Accountin8 Stsndards anLI 4p￿1(able1•Wl, Under tompany law the trustees must not approve the financial Statements uthle55 they are 5a115tled that they give a true and falr view ef the State ol affair5 of the charitable cornpony and of thÈ 5ncomln8 rE50urces and application of resources. Includln8 the Income and expendlture,¢f thecharttablecompanylorthat perbd, In preparin8th05eflnan¢lal statements, thetrusteE5are requSred to selett suitable accountlngpollcles and then apply them con515tentlvi obseThÈ the methods and prlnciple5 in the Chèritle5 SORP.. make judgement5 and estlmates that are reasonable and prudent., preparè the financlal Statements on the iolng concern bèsls unle$5 It & InapproprhtÈ to presume that the charStable CoM￿nY wlll tontlnue In buslness. The tru5teesare respon51ble forkeepinE proper at¢ountln8 record5 whlch dls¢105ewlth reasonable accuracy ata￿V￿rnetheflnan£lal position of the chèrltable rompanyand to enablethem to ensurethat the financial statement5 cornplywlththe Companle5Act 2006. They are also responslble for safe8uarding the assets of ihe charltsble company and hence for taking reasonable steps for the prevention and detecU¢n of fraud and other l¥re8ularitles. In so far a5 the trusiee5 ère aware.. thore Is no relevant audlt informatlon ol whl¢h the charltable company's audltors are unaware.. and trustees have taken all steps thèt they ought to have taken to make themsefves aworg of anyfolevant audlt Inf¢rmatlon and to establlsh that the audltors are aware of that Information. AUDITORS The audltors, J W Hlnk5 LLP, wlll be proposed foi re-appokntment atthe forthcomlng General Meetin8. This report has been prepared In accordance wlth the speclal provlslons ol Part 15 of the COm￿nI&S Act 2006 r¢latin8 to small companle5. Approved by order of the board of trustees on 27 July 2026 ènd signed on its behalf by-. K A H Jones- Secretary Page 8 REPORTOFTHE INDEPENDENT AUD￿oR$To MEMBERSOF CURE LEU¥AEMIA OplThlon We have audtied the finandal 5tatemÈnts of Cure Leukaemla Ithe'chbritable company'l for the yèar Ènded 31 Ortober 2025 whlch comprise the Statement of Nnancial AttDiitles, the Balance Sheet, the Cash Flow Ststement and fftotes to the finanual statements, includin80 summary of sSBniflcant accountln6 policies. The finantial reportln8 framework that has been applied in t￿1￿ wepèration 15 appllcable law ènd United Klngdom Accountlng Standards Iunited Klngdom Generally Accepted Actountlng Pr￿￿￿), includln8 Financiol Reporting Standard IQ2 Yhe Flnantial ReporUnRStsnthrd applScable in the UKand Republk of Ireland,. In our oplnlvn thefinancial statements.. g￿e a true and fair vlew of the stats of the£harltable company's affairs as at 31 October 2025 and of Its Incoming resources and application of resources, Includlng its intome and expenditure, forthe year then ended. have been properly pre￿red in accordarto wkh United Klngdorll GÈnerally Acceptsd Accountln8 Practlce. Includlng Financlal ReFx)rtln8 Standard 102 The Finandal Reportlng Standard applitable In the UK and Republlt of Irel8nd': and have been prepared In accordènce wlth the requlrements of the Companles Aa 2UJ6. Ba515 lor opln We conducted our audlt In accordance wkh Int￿natIonal Standards on Audltln8 IUKI IISAS IUKII ond applkable law. Our respon5ibllkiÈs under those stand3rd5 are furtheidescrlbed in the Auditors, responslbSllt*5 for the audit of the financl315tatements sectlen ofour rep¢rt. We ère independentofthe tharltablecompany In accordance withthe ethltal requlrementsthat are relevant to our audlt of t*e flnanclal 5tatem@nts In the UK, Includlng the FRCS Ethlcal standard, and we hè¥e hjlfllled our other ethlcal respoD5ib511tie5 In accordance wlth these requlrements. We belleve th•t the audlt evidence wv have obtslned 15 5uffi¢lent and appropriate to provlde a ba515 for our oplnlon. CorKlu$6Dns r•lbWn¢tO801Th8 concvn In audltlng the flnon¢lal statoment5, we hove Concluded that the trustees, use of the 8oln8 ¢oncern bas15 of accountln8 In the preparatlon of the flnanclal statements Is •pproprlate. 8ased on the work we have performed, we have net Identlfled any matÈrial uncertalntle5 rqlatln8 to events er condltli)ns that, Indlvlduolly or collectNely, may ca5t518nlficantdoubt on the Char￿ble company's ablllty to continue as a 8olnA concern for 8 perlod of at least ￿efve mot)ths from when the flnancial statements are authorfsed lor Issue, Our re5ponslbllhles and the respon￿tI11thes of the Irustee5 wlth respR¢t to goln8 concern •re described in the relevant sections of thls report. Other Irthm•tlan The trustee5 are resp)nslble for the other informatlon. The other Inl¢rmatlon compr15es the Informatlon Induded In th¢ Annuèl Report, other than the flnanclal statements and our Report of the Independent Audltors thereoh. Our oplnion on tho financ+èl staternents does not cover the other Infprmatlon and. except to the extent otherw15e •xpIltl￿Y stated our report, we de not expre55 any form Qf assurance conclu51on thereon. In connection wlth our audlt of the financial statements, eur iesponsiblllty15to roadthe other Information and, In dolnB $0, conslder whether the other informatlon Is materially In£onsistÈnt wlth the flnancial Statements or our knowledge Dbtalned In the audlt or otherwise appear5 to be materlèlly mI55tated. If we Identlfy such material intonslstencles or apparent rnaterlal mlsstaternent5, we are requlred to detormlne whether thls glve5 r15e to a material mlsstatement in the financial Statements themsefves. If, based on the work we have perlormed, we conclude that there 15 a material mlsstatement Df thls other Information, we are requlred to report that fart. We hwe nothin8to report In th15 regard. Opinionson other malters prexdbed by the Cofflp*nl•s Aci I￿6 lth our oplnion, based on the work undertaken In the coursÈ of the audlt.. the informatlon given in the REPOrt ol the Tw5tee5 for the flnanclal year for whl¢h the flThantlal statements are prepared Is consistent wlth the financlal statements.. and tho Report of theTrustees has been prepared In accordance with appllcable legal requirements. Page 9 REPORTOF THE INDEPENDENT AUDr￿RsTo THE MEM8EASOF CURE iEUKAEMIA Matters on whi¢hwe ève rtguired to repuvt by exceptkn In the118ht of the knowledge and understsndinE of thÈ charitsble company and Its gnvironmontobtsined In tF* course of the audit, we have not identified material mlsststemÈnts In the Report of the Tru5tee& We hwe nothlng to report ITr r85pert of the followlng matters where the Compan￿$ Act 2W6 requlre5 U5 to report to you ￿. in our oplnion.. adequatÈ accountln8 records have not been kept or returns adequate for our audSt have not been received from brarKhe5 not visited by us., or the flnanclal ststements are not in agreement w¢th the iccounting records and returns. or certaln disclosures of trustees, remuner3tloD speclfled by lawore not made,. or we have not retsi¥ed all the Informatlon and explanatlons we requlre for ouraudit, or the trustee5 were not entlded to take 3dvantage of the small companles, exemptlon from thÈ requlrementto prepare a Strate¥lc Report or In preparin8 the Report of theTrusiees. RespOn￿bIlItIeS of tru5t••5 As explalned more fully in the 5tstement of Tru5tees' RespDnslblllt5es, the trustees Iwho are also the directors of the charltèble company for the purposÈs of company lawl are responsible for the preparatlon of the fl￿ncIal statements and for bElng 5atlsfled that they wve a true and lair vlew. and for such IntÈrnal control 45 the trustees determlne 1$ neces58ryto enable the Prepara￿0￿ of flnanclal statementsthat are free from materlal misstatement, whether due to fraud or error. In preparlng the financlal st*ements. the trustees are responslble for assessln8 the charitable compènrfs ab+llty to tontlnue as 801n8 toncern, dlsd051n8, as applicable, matters related to go￿￿&¢0n(ern and uslng the 80ITh8 concorn bashs of accountin8 Un￿$sthe trustees elther Intend to liquSdate thÈ charltable cgmpany o¢to cease operations. or have no reallstie alternatlve but to do so. Our I￿pU￿5$bIlItIeS lllr the •udlt of th• flnan¢l•l S¢atemeb)ts Our oble¢tlves aro to obtsin reason4ble assurance about whether the flnanclal statement5 as a whole are flee from mateflèl misstètÈment, whether due to fraud or erior, and to Issue • Report of the IndepeTrdent Audltors that Includes our opit)ion. Reasorta￿e assurance Is a hS8h level of assurance but 55 not è guarantee that an audlt conducted In accordance wlth ISAS IUKI wlll alway5 detect a materlal misstatement when it exist5. M1$5tatÈments can arlse from fravd or error and ore considèred rnaterial If, Indivldually Or in the a8gregate. they Could reasonawy be expe¢ted to Intluenc¢ the economic declsions of u5eis taken on the basls of these nnandal #ètements. The extent to whSth our procedure$ are capable gf detetting Irregularltles, includlngfraud15 detèSled below.. Irregularitles, Including fw4ud, are Instance5 of nonecrease in ¢rodltors 105,Z78 28199 33,079 113,4141 13.117 116,5271 11721 3,651 15,5631 262,006 21YJ,8Y)I 14,5171 14,2171 38.3S3 N•t ￿1h kv*ld•d by op•r•tbons 77,664 75,521 ANALYSIS OF CHANGES IN MET FUNDS At 1.11.24 Cash ftow AI 31.10.25 N•tC•sh Cash at bank 183M64 51.705 131759 113M64 151,7051 Tot•1 183J64 51,7051 The nDtes form part of these financial statements Page 15 CURE LEUWMIA NOIE5TO THE FINA14CIAL WATEMENTS FOR THE YEAR ENDED 31 ocfoBER2025 ACCOUNTING POLICIES GENERAL INFORMATION AND BASIS OF PREPARIPIG THE FINANCIAL5TATEMENTS GÈn¢r•l knformatknn Cvre Leukaemla Is a charltylncorporated In England ènd Wale& The addfessolthe charlty's re8lStered office Is 19 H58hfleld Road. EdgbastoTh. blrmin8ham, West Midland5, 815 3BH. ¢¢YJntI￿ convèntlon The nnanclal ststements of the ¢h)rity, which is a public benefit entlty under FRS 102, have been prepared In accordance with the CharSties SORP IFRS 1021 Attountlng and Rewrung by Charlties.. Statement ol Recommended Practite appllcable to charltles preparlngtheir account5 in accordance the Flrtancial Rèporting Standard applicable In the United Kingdom and Republ1¢ of Ir@land IFRS 1021 Financial fieportingstandard 102 'The FSnancial Rewrtln85tandard appllcable In the UK and Republ1¢ ol Ireland the Companie5 Act ZLh)6 and the CharltSes Act 2011. The financ+al statements have been prepared ulng the hlstorlc cost conventlon as modifled by the revaluatlon of Investments and 3re presented in sterlln8, whl¢h is the funrt￿nal currency of the charty, rounded to the nearest El. Thesi8niflcantaccounting wlice5 applied In the preparatlenofthe5efinarKialstat¢mentsare setout below. These pollcles have been CDn515tently applled to 411 ye3r5 presented unle55 Otherwl$e stated. COMPANYSTATUS The charity is a company Ilmlted by guarantee. The rnembers of the charltable eompany are the trustee5 named In the Reportof theTru5tees. In the event of the charlty beln6 weund upthe Ilablllty In respertof the guèrantee15 Ilmlted to £10 per member of the charltv. GOING CONCERN The flnoncial Statements have been prepared on a 8oln8 concern bas15aSthetrusteÈ$ believe that materlal uncertalntles exlst, Thetrustees have considered the level of funds held and theexperted level of Incomeandexpendttyre for 12 months from authorisln8 these fit)anclal st3tements. The expectod level of income and expendlture Is suffi'cient with the level ol reserves forthe charlty to able to contlnue as a going concern. IIICOME All Incom•15 recognlsed In the St*ement of Flnanclal Activitles on¢• the Char￿ hès entitlernentto the fund5,' It Is probable that the Income wlll bè recelved and the amount can be measured rèllablv. Donation5 lexcept In relatlon to leEaclesl arE accounted for when recelvable. If there are conditlons attached to the donatlon and thls requlros a level of performance before entltlement can be obtalned, then Income Is deferred until those tondltion5 are fully met Dr the fulfilment of those conditlons Is wlthln the control of the charity, and It is probable that they Incprne from pecuniary legacles Is reco8nised where grant ol probate has been recelved ènd Income from reslduary le8acie5 Is reco8nlsed where estate accounts have been hnalised. Income from w5119 or reverslonary trust5 of property 15 not reco8nlsed untll the Ilfe Snterest ha5 passed awèy and the property Sale is at an advanced 5ta8e. Income from all other legacles is only reco8Thlsed where there15 clear entitlement, the omount be accurately meo5ured and their reasonable probability of recelpt. ThÈ receipt of le8aCiÈ5 15 cansldered probable when probate ha5 been granted, It ha5 been e5tabllshed thatthere are sufficient net a55etsto paythe legacy and anycondltlons attachEdtothe le8acyhave been met or are undei the control of Cure Leukoernia. The chaTity receives 8rènt5 fTcm otherthlrd partie5 In respect of itsactiyitles. Gram Incomelsieco8nised atfairvaluebyhe rhe charity ha5 entytlementafter any performance condition5 have been met, it is probable that the income will be recelved andthe amountcèn be measured reliab￿. If Èntrtlement Is not met, then these amounts are deferred. Income received from fundralsing act1v1t￿$ or83Thised by ]nd￿idUal5 or volunteer Erc>ups operating frem out51de of thq charfws control is reco8nised when recelvable. Incorne relatln8 to the core ryclin8 an¢1 runnlngevents are accounted for Dn recelved basis In aCcOrda￿e with the terms ènd conditljns of the participant ayeements. Pa8e 16 contlnyed.. CURE LEIMAEMIA NOTES TO THE FINANCIAI STATEMENTS- conilnL*d FOR THE YEAR ENDED 31 OCTOBER Z015 ACCOUNTING POLICIES. cort￿n￿ed INCQME Investment Incoffle is earned through holding a$5et5 Itr Investment purKK)ses such as 5hare& It Includes dfvSdends and interest recewable. Where It is not practicable to Identkly Investment ffl3nagÈment costs Incurred within a scheme with reasonable accuracy* investment Income 15 reported net of ihese costs. It is included when the amount can be measured reliably. Interest income is recognised u5in8the effe¢fjve Interest rate methud and dlvldeThd IncomE Is recognlsed ￿ the tharlvs ilght to recelve paymÈnt Is estab115hed. Thevalue for Brfts in klnd. donated se￿(e$ and donated facllltles are q5￿M￿ted Included In the perSod inwhlch they ore re£dved. In accordance wlth Charlties 50RP IFRS 1021 gÈnÈral volunteertirne is not recoinlsed. EXPENDITURE L5abilltie5 Ire recognised as expenditure as soon as there 15 J legal or cOnstruct￿e obllgatlon commI￿n&the chafftyto that expenditure, It is probablg that a transfer of econom1¢ beneflts wlll be requlred In settlement and the amount of the obllg*loncan bemea5ured rellobly. ExpendSture15 accounteofor on an accrua15 ba515and has beencl355ifled underheadlng5 that a88regate all c05t rdated to the c3te8uy. Where costs tannet be dlrectly attrlbuted to partlcular headln8S they have been allocated to actl¥ltle5 OTh a b•$ls conslstentwlth the use of resources. Expendittsre on raI￿n¥ lunds includes expendlture Incurred In ra151nE donatlons ind le8acles, other trodin8 4Ctivltles and Investment management rosts These cost5 are reyrded as necessary to ￿nerate funds that are needed to finance Chorltable actlvltle$ expendltur* enable5 the charfty to mew Its charltable alms and oblectlves. Supportrosts arethose that •slst wkth the work of the charlty do not dlrectpy representcharttable ocvvltlos and Include offlce costs, governance costs and other admlnlstratlve costs. Grants Dffered subject to condbtlorts whlch have not been met at the year.end dalp 4re noted a5 a cOry￿1tment but not •¢cruÈd ès expendlture. TAMTION The charlty is exempt froffl ¢orporbtl?n tax on its charIts￿e a¢t1vl￿eS. FUND ACCOUNTING General fundsare unre5tTlcted funds which ère avallablefor use atthe d15cretlon ofth¢trust¢esln furtheraThce of th¥ general blectlves of the charfty and whlrh have not teen de51gn•ted for other purposes DesiRnated fijnds comprlse unrestrlrt4d lunds that have been set aslde by the trustees for particular purposes. Restrlcted funds dre lunds whlch are to be used In accordance with speclflc restrlctlons Imposed by donors er whlch have been ralsed by the charlty for partl£ulaT purposes. The cost5 of raisin8 and admln15teriThg 5vch funds are charged ogalnst the specffic fund. Further explanatlon of the nature and puipo5e gf eath fund Is IrKluded in the notestothe financlal ststernents. FINANaA INsfRUMENfs The charityonty hè5finonclal assets and financlal liabillties of a klnd that quallfy as baslcfinaThclal Instrumonts. Basit financ￿1 Instrurnents are initialty reco￿lSed ottran5aCtion value and subsequen￿Y measured at amortlsed cost, CRincAL AccouMfiNG EsfiMATES AND JUDGEhlENTS In the application of the charity's accountinE pollcies, the tru5tee5 are required to make judgernen￿ gstimatss and •ssumptlons aboutthe ¢arrying amount of a55et5 and liabilitles that are not readity apparent from other 51HJrcÈs. ThÈ estlmètss and underlylng assumptlons are revlewod on an ongolng ba515. Revlslons to accounting estimates are reco8nised Sn the period in which thE estimate is revised where the revision affetts only that perbd or in the perlod of the revi&on andfuture periods wherÈ the revlsSon afFects both turrent and future pefiads. Page 17 continued... CURE LEUKAEMIA TE5TO THE FINANCIAL￿ATEMe1￿T5-conl￿nuId FOR ThE YEAR ENDED31 OCTOBER ZQZ5 ACCOUNTING POLICIES- conwnued FOtIE16N CURRENaES A55ets and 1Sabilltle5 in foreign ¢urrenThes are translated Into 5terlln8 at the rat95 of exchange ruling at the balance sheet date. Tran5actionslnforeS8ll turTencles 2retron51ated Int05terlinE atthe rateof exchan8eiulln8at the dète of transattion. ExEhange dlfferen¢e5 are taket) Into account In arrhAn8ltthe opÈraJng result CASH AND CNSH EQUIVALENTS Cash at)d cash eouNalents In¢lude cash In hand and deposits held at call with banks. OPERATING L£￿E5 Renta15 pay3Ne under opÈraYn8 leases are cha¥ged against Income on • straight-llne bas15 Over the perlod Df the lease. INVESTMENTS Investments are reco8ni5ed inltlèlly at falr value whlch 15 normally the tranS￿li0n prite excludln8 tr3n5attlon costs. Subseguentty. they are measured ai fair value whh chan8es reco8n15ed In 'net 8lln5111055esl on Investments" In the statemÈntof Financlal Artlvltleslf the InvestmentsarÈ publKlytraded or thelrfair Value tan otherwlsebe rnea5ured rellably. INTAJIGIOLE FIXED ASSETS FIMed assets are Snitlally rEco8nlsed èt cost or falr valuation and revlewed annually for Impairment. Computer software Is amortI5ed evenly over Its useful economiclile of 3 years. Website tosts are amortlsÈd e￿nlY ower thelr usqfvl economlc Ilfe of 5 years, EMPLOYEE BENEFITS When employees have rendered 5ervlce to the charlty. 5hort-term employee benefit5 to whlch the ernployees are entltled are retognlsed at the und15countea amount experted to be pald in exrhan8e for that sÈrvlce. Temilnatlcn benefits •re rqcognlsed Immedl*ely as an e¥pense when the charlty Is demonstrably commltted to teimlnate the employment of In employee or to provlde termlnatlen benefit$. GOVERNME1￿ GRANTS Government 8rantS 3re recosnised at the falr value of the asset recow or recefvable when there 15 reasonable assurance that the 8rant conditlon5 wlll be met and the grants wlll be received. A 8rant that spedfies performan¢e conditknns is r*Eognlsed in In¢ome when the performance condlfjons are met. Where 8rant does not spEcify performèrte condltlons it15 reco8nlsed In Income when the proceeds ère received or recelvable. A 8rant recelved before the recognition crjterla are sat151￿ed Is r•co8nised as a Ilability. DONATIONSAND LEGAUE5 2025 2024 Oonauons and glfts Legxles 167,lQ5 Jo0,￿0 76,146 467,105 76,146 Pa8e 18 wntinued... CURE LEUWMIA NOTESTOThE FIIIANCIAL STATEMENTS. ¢ontlm*d FOR THE YEAR ENDED 31 ocfo8EA 2025 OTHER TIiADING AcnvmES 2015 2024 Fundfalslngevent5 2,921.354 2.516,083 INVEfft￿ENT INCOME 2024 Quoted flxed a55et Investmenls Deposbt account Inter@5t 5.563 172 5.735 IIKOME FROM CHARITABLE AcnviriE5 2025 2024 Actmty Grants recelvable Gr•nts 315mO Grants re£8lved, Included In the above, are 45 follows.. Unr•slvlrted lunds ft•51rlct•d 2025 2024 The 5yncona Foundatlon Garfleld Weston Foundation The Broome Famlly CharltablÈ Trust The Acces5 Foundation Mazars Charltable Trust The Hosltal Saturday Fund 150,WO 150,WQ 0.000 150,WO lo,￿0 15O,IX 150.tt io,¢yx) 500 ID.oJo 315.000 31S,WO RAISIP46 FUNDS RJJSING OOPIATIONSAND LEfAciES 202$ 2024 Athertlsingand marketln8 Wvb5itÈ development IXhÈr voluffiary Income costs CRM ¢osts 145.281 ii,oio SZ 44.437 4&511 39.U7 231936 115,563 Page 19 conunued.. CURE LEUKAEMIA NOTESTOThE FINANCIAL sfATEMEiifs. (Ofillnued FOR THE YE14R ENDED 31 ocfooER 2015 AISING FUNDS- cohtlnu•d OTHER TRADING AcnvmES 1025 2024 Event etr5ts Staff w5ts 1,513,65S 738.260 1,589,565 638 207 2251,915 2,227.772 INVESIMEpif MANAGtMENTC0$7S 2025 2024 Portfollo managemeni Awegate amounts CTrINAITP3￿ AcrnirriES COSTS Grant lundlng of attlvltles lsee note 81 Support Q5ts (see note gi Tots15 Wages Insurance Postage an¢J 5t*ionery 5undrles Travel expenses Telephone Computer consumable$ Grants payable Office utllltles Legal and professlonal fees Recrultment Amorti5atlon and dopredatlon 42,750 7,953 10,922 35,115 ID.J80 42.750 7.953 10,922 35,115 20.380 13.831 1S.LM)8 832.278 47,671 55,228 16.200 53.079 832278 47.671 55,218 16,200 33J)79 832.178 298,lJ7 1,130A15 GRAN15 PAYAOiE 2025 2024 Grants payable Release on urrlalmed 8rant reserves 83Z378 8B5,651 582,8551 832,178 302,796 Durlng the year ended 31 Ortober 2025 the charlty madethe fcllowlng grants order to contribute toward5the fundlngof leukaemia research progrommes and towardsthe taTe of patlents suffering from leukaemia. Pa8È 20 conlnued... CVRE LEUVAEMIA NOTESTOTHE FINANaALSTATEMEPITS- wntlnwd FOR THE YEAR E14DEts 31 ocfoBER 1025 GRANTS PAYABLE. ¢ontlrwÈd Tgtal 8fartts payableto instiwtlons duringthe year were è5follows'. 2025 2024 ReOonal res•èth Dlrect TAP network and 5UPPOrt AccolÈratin8 Cllnkal Trfals LlmhÈd (Acri 17.270 815￿(17 1437.2041 740.000 832378 302,796 Grants payable are £harBed In the yeaf when the offer15 convqyqd to the redplent except In those cases where the offer Is Ddbtlonal, such grant5 belng re¢ognlsed as expendSture when the conditlons are fulfilled, SUPPORT COSTS Support costs are those cost5 that have been Sncurred by the rharity In order to further the ¢ontlnued development of the Charlty'slundral￿nrf and chorltsble attivltles. io. NET IKOMEIIEXPEMDITUAei Net Incomellexpendlturel is ststed aftor charl1n￿(CredItlTh1)'. 2025 2024 Webshe amortlsatlon Ctynputer software amortisatlon 1.200 31,879 13,117 ii. AUDITORS. REMUNEIiATION 2025 2024 Fees payat4e to the charlty's audltorsfor the audlt of the char￿,$ flnanclal st¥tÈmenis (Xher non-audlt 5ervlce5 8,8ZO 2,201 l5Jl 12. TIWSTEES, REMUNERATION AND BENEFITS ThpAe wÈre no tru5tees' remungrafjon or other benefbts for the year ended 31 October 2025 nor for the year ended 31 Octuber 2024, TRU5fEES' EMPENSES Thw& w¢re no trustees, empenses paidfor the year ended 31 October 202S norforthe yeor ended 31 October 2024. Page 21 continued... CURE LELIKAEMIA NOTESTOTHE FINANCIALSTA7EMEPITS.contlnued FOR ThE YEAR ENDED 31 OCTOBER 1025 STAFFC05f5 2025 2024 Wages and salaries Soclal securftyc05ts Other pension costs 700A36 69.873 10.701 602,556 61,042 8,686 78LOIO 672,284 The avetage rrKsnthly nymber of em￿0veeS durlngthe year was 15folbws'. 2025 io X)24 Management and adminlstratlon The number of employee$wh05e employee benefits lexcludlngemployer pensl¢n ¢ost51 ex￿￿ed £60.OCpJ was.. £160.001- £170,¢JX• £180,001- £190.000 2024 114TANGIBLE FIXEDA8SETS Computer software Webslte Totsls COST At l November 2024 Addltlons 59.026 72,811 S9,026 144 72,000 At 31 October 2Q25 IJL837 205.837 AMOftTISATION At l November 2024 har8e for year 13.117 31,879 11,117 At 31 Ottober 2025 46,196 NET BOOKVNIUE At 31 Ottober 2025 8&841 157,641 At 31 October 2024 45,909 45,909 Page 22 continued... CURE LEUKAEMIA NOTE5 TOThE FINAKIAL sfATEMEpifs. cuntlnwl FOR ThE YEAR ENDED 31 ocfoBER 2015 Is. FIXED ASSET INVE¥NEpif5 202S 2024 Market value at l November 2024 Additlon5 at cost Sale proceeds on disposal Aeallsed and unreo115ed 6alnll10551 In the year 168N96 37.991 137,7981 13A14 150.833 42,592 141,4561 16,527 M8r*et¥alue3t 31 October 2025 Cash on dep051tas at 31 Ortober 2025 182.103 168,496 Totsl market value of In¥estment5 45 * 31 ooober Z025 190.965 174,880 Hlstort costat 31 October 2025 175,523 170,797 ANALYSIS OF IPIVE5TMENTS 2025 2024 LIK quoted equltle5 and bonds 14on-UK quoted equitles and bonds 146,577 35.526 148.185 20.311 181,lOJ 168.496 6.364 Cash held for relnvestment 174 880 16. OEBTORS.. AMOUNTS FALUNG DUE WnHIN ONE YEAn 2025 2024 Tr•de debtor5 Other dobtors Prepaymlnts J07M45 126,886 9,051 215.115 229.228 443382 452,569 17. CREI)ITOR5: AMOUNTS FAiLING DUE WThHIN OT4E YEAR 2025 2024 SDrlal se¢urity Ind othertsxes Other trÈdltors Accrua15 and dRfotyed Income 62805 2W924 16,882 342,930 39,220 360,679 399.032 Page 23 continued... CURE LEWEMIA NOTESTOThE FIP4*MIALSTATEMENfs-conWnued FOR THÉ YEAR EI4DED 31 ocfoBER 2025 LEA51N6 AGAeEMEpirs At 31 October 2025 the clwrlty had out